Changzhou Qianhong BiopharmaLTD Third Quarter 2024 Earnings: EPS: CN¥0.10 (vs CN¥0.062 in 3Q 2023)

Simply Wall St · 10/18 22:33

Changzhou Qianhong BiopharmaLTD (SZSE:002550) Third Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥352.0m (down 14% from 3Q 2023).
  • Net income: CN¥126.8m (up 61% from 3Q 2023).
  • Profit margin: 36% (up from 19% in 3Q 2023). The increase in margin was driven by lower expenses.
  • EPS: CN¥0.10 (up from CN¥0.062 in 3Q 2023).
earnings-and-revenue-growth
SZSE:002550 Earnings and Revenue Growth October 18th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Changzhou Qianhong BiopharmaLTD Earnings Insights

Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are up 12% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Changzhou Qianhong BiopharmaLTD you should know about.